Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Pfaar, O; Agache, I; Bergmann, KC; Bindslev-Jensen, C; Bousquet, J; Creticos, PS; Devillier, P; Durham, SR; Hellings, P; Kaul, S; Kleine-Tebbe, J; Klimek, L; Jacobsen, L; Jutel, M; Muraro, A; Papadopoulos, NG; Rief, W; Scadding, GK; Schedlowski, M; Shamji, MH; Sturm, G; van Ree, R; Vidal, C; Vieths, S; Wedi, B; Gerth van Wijk, R; Frew, AJ.
Placebo effects in allergen immunotherapy - an EAACI Task Force Position Paper.
Allergy. 2020;
PubMed FullText FullText_MUG

 

Autor/innen der Med Uni Graz:
Sturm Gunter
Altmetrics:

Dimensions Citations:

Plum Analytics:
Abstract:
The placebo (Latin "I will please") effect commonly occurs in clinical trials. The psychological and physiological factors associated with patients' expectations about a treatment's positive and negative effects have yet to be well characterized, although a functional prefrontal cortex and intense bidirectional communication between the central nervous system and the immune system appear to be prerequisites for a placebo effect. The use of placebo raises certain ethical issues, especially if patients in a placebo group are denied an effective treatment for a long period of time. The placebo effect appears to be relatively large (up to 77%, relative to pre-treatment scores) in controlled clinical trials of allergen immunotherapy (AIT), such as the pivotal, double-blind, placebo-controlled (DBPC) randomized clinical trials currently required by regulatory authorities worldwide. The European Academy of Allergy and Clinical Immunology (EAACI) therefore initiated a Task Force, in order to better understand the placebo effect in AIT and its specific role in comorbidities, blinding issues, adherence, measurement time points, variability, and the natural course of the disease. In this Position Paper, the EAACI Task Force highlights several important topics regarding the placebo effect in AIT such as i) regulatory aspects, ii) neuroimmunological and psychological mechanisms, iii) placebo effect sizes in AIT trials, iv) methodological limitations in AIT trial design and v) potential solutions in future AIT trial design. In conclusion, this Position Paper aims to examine the methodological problem of placebo in AIT from different aspects and also to highlight unmet needs and possible solutions for future trials. This article is protected by copyright. All rights reserved.

© Med Uni Graz Impressum